These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 32103537

  • 1. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T, Aihara M.
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
    Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H, UKMyoNet.
    Rheumatology (Oxford); 2019 Apr 01; 58(4):650-655. PubMed ID: 30535395
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
    Yang H, Yan T, Zhang X, Sun W, Liu L, Du Y, Xue J.
    Clin Rheumatol; 2022 Aug 01; 41(8):2439-2448. PubMed ID: 35422109
    [Abstract] [Full Text] [Related]

  • 6. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y, Ishikawa A, Sugiura K, Akiyama M.
    Rheumatology (Oxford); 2012 Aug 01; 51(8):1508-13. PubMed ID: 22539482
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
    Fiorentino DF, Mecoli CA, Rosen MC, Chung LS, Christopher-Stine L, Rosen A, Casciola-Rosen L.
    J Clin Invest; 2022 Jan 18; 132(2):. PubMed ID: 35040440
    [Abstract] [Full Text] [Related]

  • 9. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
    Dani L, Holmqvist M, Martínez MA, Trallero-Araguas E, Dastmalchi M, Svensson J, Labrador-Horrillo M, Selva-O'Callaghan A, Lundberg IE.
    Clin Exp Rheumatol; 2020 Jan 18; 38(1):67-73. PubMed ID: 31365334
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
    Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N, Maezawa R, Arai S, Kurasawa K, Ito K, Shimada H, Iwanami T, Sonoo M, Hatanaka Y, Murayama S, Uchibori A, Chiba A, Aizawa H, Momoo T, Nakae Y, Sakurai Y, Shiio Y, Hashida H, Yoshizawa T, Sakiyama Y, Oda A, Inoue K, Takeuchi S, Iwata NK, Date H, Masuda N, Mikata T, Motoyoshi Y, Uesaka Y, Maeda MH, Nakashima R, Tsuji S, Kwak S, Mimori T, Shimizu J.
    Neurology; 2016 Jul 19; 87(3):299-308. PubMed ID: 27343066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, Miller FW, Rider LG, Childhood Myositis Heterogeneity Collaborative Study Group.
    Rheumatology (Oxford); 2021 Apr 06; 60(4):1839-1849. PubMed ID: 33140079
    [Abstract] [Full Text] [Related]

  • 18. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Kono M, Akiyama M.
    Clin Exp Rheumatol; 2018 Apr 06; 36(6):990-995. PubMed ID: 29745874
    [Abstract] [Full Text] [Related]

  • 19. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
    De Vooght J, Vulsteke JB, De Haes P, Bossuyt X, Lories R, De Langhe E.
    Rheumatology (Oxford); 2020 Mar 01; 59(3):469-477. PubMed ID: 31883334
    [Abstract] [Full Text] [Related]

  • 20. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
    Yoshida S, Matsumoto H, Fujita Y, Yokose K, Temmoku J, Matsuoka N, Yashiro-Furuya M, Asano T, Sato S, Suzuki E, Yago T, Yaguchi T, Aita T, Kusano M, Yamamoto T, Watanabe H, Migita K.
    Tohoku J Exp Med; 2022 Apr 20; 256(4):303-308. PubMed ID: 35296571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.